公司目前已服務超過10,000家客戶遍布高校、研究所、醫(yī)院、生物制藥、基因測序等企業(yè)客戶。在上海、北京、廣州、深圳、香港等全國主要城市設有管理和營銷中心,并在美國、澳大利亞和烏拉圭設有分公司。
In 2023, Saiguo Biotech once again obtained the first-level authorization letter of ExCell Bio.
Founded in 2013, with the mission of "accelerating the application of life science and technology and benefiting the health of the people", ExCell Bio is committed to solving the neck of biomedicine and realizing the localization of key raw materials, and has now become one of the leading enterprises in China's biomedical upstream core raw materials. The company is a national high-tech enterprise, a national specialized and special new small giant enterprise, China's first member unit of the International Serum Industry Association (ISIA), and a CD serum-free media engineering research center in the fields of biopharmaceuticals and cell therapy in Jiangsu Province.
The company currently focuses on three major product segments, including serum-free culture media, fetal bovine serum and identification reagents, and provides international quality products and services for customers in biological drugs, cell and gene therapy, and basic scientific research. Relying on the international and professional R & D technical team, quality and production team and commercialization team, the company continues to innovate, pursues excellence, ensures reliable quality and stable supply while continuously optimizing product performance, fully empowers the rapid and healthy development of the biomedical industry, and creates cell culture "Chinese core" products.
At present, the company has served more than 10,000 customers in universities, research institutes, hospitals, biopharmaceuticals, gene sequencing and other enterprise customers. It has management and marketing centers in major cities such as Shanghai, Beijing, Guangzhou, Shenzhen and Hong Kong, and branches in the United States, Australia and Uruguay.
【2023/1/3 12:40:02】